In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Akebia Therapeutics (AKBA), with a price target of $6.00. The company’s shares closed last Friday at $3.39, close to its 52-week low of $2.09.
According to TipRanks.com, Yang ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -6.9% and a 35.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Xeris Pharmaceuticals, and Sarepta Therapeutics.
Akebia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $7.33, an 116.9% upside from current levels. In a report issued on June 1, Needham also maintained a Buy rating on the stock with a $10.00 price target.
See today’s analyst top recommended stocks >>
Akebia Therapeutics’ market cap is currently $533.2M and has a P/E ratio of -1.20. The company has a Price to Book ratio of 22.79.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AKBA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
